| abstract |
FIELD: biotechnology, virology, medicine.SUBSTANCE: disclosed is vaccine which is a mixture of following adenovirus vectors based on human adenovirus serotype 5 with deletions in the regions E1 and E3 of the genome, wherein the adenovirus vector carries an expression cassete with the insertion of the target gene, selected from the list: a gene having a sequence with an identity of more than 92% with SEQ ID NO: 1, a gene having a sequence with an identity of more than 89% with SEQ - ID NO:-2, a gene having a sequence with an identity of more than 84% with c-SEQ-ID-NO: 3, a gene having a sequence with an identity of more than 84% with SEQ ID-NO: 4, a gene having a sequence with an identity of more than 99% of SEQ-ID NO: 5, and also the vaccine contains a pharmaceutically acceptable buffer solution. Also disclosed is the use of the vaccine - for the induction of immunity against influenza type A, influenza type B and COVID-19-by administrating the vaccine intranasally or simultaneously intranasally and intramuscularly.EFFECT: the group of inventions allows creating an effective and safe vector vaccine against respiratory infections of epidemiologically relevant single-stranded RNA viruses: influenza A subtype H1, influenza A subtype H3, influenza B lineage Yamagata, influenza B lineage Victoria, SARS-Cov-2, and creating intense immunity to each of these viruses at the same time. The invention can be used for the simultaneous prevention of respiratory infectious diseases in the population caused by epidemiologically relevant single-stranded RNA viruses, such as influenza viruses of types A and B, coronavirus SARS-Cov-2.9 cl, 22 dwg, 2 tbl, 9 ex |